# First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

Source: https://onco.cc/trials/nct06625515/  
OnCo record `nct06625515` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ATX-559 run by Accent Therapeutics, terminated.

## Summary

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers is a phase 1 interventional study registered as NCT06625515 by Accent Therapeutics, with 17 participants enrolled, started 2024-10-11. Conditions recorded: Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma and Endometrial Cancer. Interventions recorded: ATX-559.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06625515
- Phase: 1
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients With Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers
- Sponsor: Accent Therapeutics
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT06625515: https://clinicaltrials.gov/study/NCT06625515

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- drugs: [ATX-559](https://onco.cc/drugs/atx-559/)
- companies: [Accent Therapeutics](https://onco.cc/companies/accent-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06625515.json